Glenmark Pharmaceuticals Limited
2,091words
0turns
0analyst exchanges
0executives
Key numbers — 40 extracted
rs,
August 14, 2025 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager – Listing, National Stock Exchange of Indi
Rs. 32,644
uticals Ltd. All Rights Reserved Q1 FY26 Summary Consolidated Revenue • Consolidated Revenue of Rs. 32,644 Mn • YoY growth of 0.6% Regional Highlights • US Business QoQ growth of 8.9% • India business Yo
0.6%
d Q1 FY26 Summary Consolidated Revenue • Consolidated Revenue of Rs. 32,644 Mn • YoY growth of 0.6% Regional Highlights • US Business QoQ growth of 8.9% • India business YoY growth of 3.7% Profit
8.9%
d Revenue of Rs. 32,644 Mn • YoY growth of 0.6% Regional Highlights • US Business QoQ growth of 8.9% • India business YoY growth of 3.7% Profitability • EBITDA at Rs. 5,805 Mn • EBITDA margin of 17
3.7%
owth of 0.6% Regional Highlights • US Business QoQ growth of 8.9% • India business YoY growth of 3.7% Profitability • EBITDA at Rs. 5,805 Mn • EBITDA margin of 17.8% • Adjusted PAT1 at Rs. 3,129 Mn
Rs. 5,805
s • US Business QoQ growth of 8.9% • India business YoY growth of 3.7% Profitability • EBITDA at Rs. 5,805 Mn • EBITDA margin of 17.8% • Adjusted PAT1 at Rs. 3,129 Mn with Adjusted PAT margin of 9.6% 1 A
17.8%
9% • India business YoY growth of 3.7% Profitability • EBITDA at Rs. 5,805 Mn • EBITDA margin of 17.8% • Adjusted PAT1 at Rs. 3,129 Mn with Adjusted PAT margin of 9.6% 1 Adjusted for the Exceptional
Rs. 3,129
rowth of 3.7% Profitability • EBITDA at Rs. 5,805 Mn • EBITDA margin of 17.8% • Adjusted PAT1 at Rs. 3,129 Mn with Adjusted PAT margin of 9.6% 1 Adjusted for the Exceptional item related to the US litigat
9.6%
s. 5,805 Mn • EBITDA margin of 17.8% • Adjusted PAT1 at Rs. 3,129 Mn with Adjusted PAT margin of 9.6% 1 Adjusted for the Exceptional item related to the US litigation settlement as highlighted in the
25%
jectable and partnered products launches. Our Europe and Emerging markets businesses have recorded >25% CAGR and >10% CAGR respectively over the last three years, and we expect the region to deliver a do
10%
artnered products launches. Our Europe and Emerging markets businesses have recorded >25% CAGR and >10% CAGR respectively over the last three years, and we expect the region to deliver a double-digit gro
0.4%
678 5,721 32,578 66 32,644 11,962 7,808 6,957 5,708 32,435 7 32,442 YoY Growth (%) 3.7% -0.4% -4.0% 0.2% 0.4% 848.4% 0.6% FY 2024-25 9,430 7,146 7,335 7,898 31,809 753 32,562 QoQ Gr
Advertisement